Ribonucleotide reductase subunit M2 promotes proliferation and epithelial–mesenchymal transition via the JAK2/STAT3 signaling pathway in retinoblastoma

References

• Jubran RF, Erdreich-Epstein A, Butturini A, et al. Approaches to treatment for extraocular retinoblastoma: children’s hospital los angeles experience. J Pediatr Hematol Oncol. 2004;26(1):31–34.
   PubMed Web of Science ®Google Scholar
• Houston SK, Murray TG, Wolfe SQ, et al. Current update on retinoblastoma. Int Ophthalmol Clin. 2011;51(1):77–91.
   PubMedGoogle Scholar
• Finger PT, Harbour JW, Karcioglu ZA. Risk factors for metastasis in retinoblastoma. Surv Ophthalmol. 2002;47(1):1–16.
   PubMed Web of Science ®Google Scholar
• Liu Q, Wang Y, Wang H, et al. Tandem therapy for retinoblastoma: immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis. J Cancer Res Clin Oncol. 2013;139(8):1357–1372.
   PubMed Web of Science ®Google Scholar
• Nordlund P, Reichard P. Ribonucleotide reductases. Annu Rev Biochem. 2006;75:681–706.
   PubMed Web of Science ®Google Scholar
• Torrents E, Aloy P, Gibert I, et al. Ribonucleotide reductases: divergent evolution of an ancient enzyme. J Mol Evol. 2002;55(2):138–152.
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Whang EE. RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness. Biochem Biophys Res Commun. 2007;354(1):190–196.
   PubMed Web of Science ®Google Scholar
• Furuta E, Okuda H, Kobayashi A, et al. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta. 2010;1805(2):141–152.
   PubMed Web of Science ®Google Scholar
• Lu AG, Feng H, Wang PX, et al. Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair. World J Gastroenterol. 2012;18(34):4704–4713.
   PubMed Web of Science ®Google Scholar
• Shah KN, Mehta KR, Peterson D, et al. AKT-induced tamoxifen resistance is overturned by RRM2 inhibition. Mol Cancer Res. 2014;12(3):394–407.
   PubMed Web of Science ®Google Scholar
• Hsu NY, Wu JY, Liu X, et al. Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer. Anticancer Res. 2011;31(10):3475–3481.
   PubMed Web of Science ®Google Scholar
• Morikawa T, Maeda D, Kume H, et al. Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. Histopathology. 2010;57(6):885–892.
   PubMed Web of Science ®Google Scholar
• Souglakos J, Boukovinas I, Taron M, et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer. 2008;98(10):1710–1715.
   PubMed Web of Science ®Google Scholar
• Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117(Pt 8):1281–1283.
   PubMed Web of Science ®Google Scholar
• Berishaj M, Gao SP, Ahmed S, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res. 2007;9(3):R32.
   PubMed Web of Science ®Google Scholar
• Liao XH, Xiang Y, Yu CX, et al. STAT3 is required for MiR-17-5p-mediated sensitization to chemotherapy-induced apoptosis in breast cancer cells. Oncotarget. 2017;8(9):15763–15774.
   PubMedGoogle Scholar
• Yuan K, Ye J, Liu Z, et al. Complement C3 overexpression activates JAK2/STAT3 pathway and correlates with gastric cancer progression. J Exp Clin Cancer Res. 2020;39(1):9.
   PubMed Web of Science ®Google Scholar
• Chang YC, Su CY, Chen MH, et al. Secretory RAB GTPase 3C modulates IL6-STAT3 pathway to promote colon cancer metastasis and is associated with poor prognosis. Mol Cancer. 2017;16(1):135.
   PubMedGoogle Scholar
• Su J, Morgani SM, David CJ, et al. TGF-beta orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1. Nature. 2020;577(7791):566–571.
   PubMed Web of Science ®Google Scholar
• Kim MS, Jeong J, Seo J, et al. Dysregulated JAK2 expression by TrkC promotes metastasis potential, and EMT program of metastatic breast cancer. Sci Rep. 2016;6:33899.
   PubMed Web of Science ®Google Scholar
• Kong PZ, Yang F, Li L, et al. Decreased FOXF2 mRNA expression indicates early-onset metastasis and poor prognosis for breast cancer patients with histological grade II tumor. PLoS One. 2013;8(4):e61591.
   PubMed Web of Science ®Google Scholar
• Yu Y, Xiao CH, Tan LD, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling. Br J Cancer. 2014;110(3):724–732.
   PubMed Web of Science ®Google Scholar
• Sun L, Zheng W, Liu QD, et al. Valproic acid protects chondrocytes from LPS-Stimulated damage via regulating mir-302d-3p/itgb4 axis and mediating the PI3K-AKT signaling pathway. Front Mol Biosci. 2021;8:633315.
   PubMed Web of Science ®Google Scholar
• Yu F, Lin Y, Xu X, et al. Knockdown of GSG2 inhibits prostate cancer progression in vitro and in vivo. Int J Oncol. 2020;57(1):139–150.
   PubMed Web of Science ®Google Scholar
• Lin ZP, Belcourt MF, Cory JG, et al. Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors. J Biol Chem. 2004;279(26):27030–27038.
   PubMed Web of Science ®Google Scholar
• Alvarez-Salas LM. Nucleic acids as therapeutic agents. Curr Top Med Chem. 2008;8(15):1379–1404.
   PubMed Web of Science ®Google Scholar
• Zuckerman JE, Gritli I, Tolcher A, et al. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci U S A. 2014;111(31):11449–11454.
   PubMed Web of Science ®Google Scholar
• Duxbury MS, Ito H, Zinner MJ, et al. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene. 2004;23(8):1539–1548.
   PubMed Web of Science ®Google Scholar
• Zeng Y, He T, Liu J, et al. Bioinformatics analysis of multi-omics data identifying molecular biomarker candidates and epigenetically regulatory targets associated with retinoblastoma. Medicine (Baltimore). 2020;99(47):e23314.
   PubMed Web of Science ®Google Scholar
• Nie C, Ma H, Gao Y, et al. RNA sequencing and bioinformatic analysis on retinoblastoma revealing that cell cycle deregulation is a key process in retinoblastoma tumorigenesis. Ophthalmologica. 2021;244(1):51–59.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li S, Cao J, et al. RRM2 regulated by LINC00667/miR-143-3p signal is responsible for non-small cell lung cancer cell progression. Onco Targets Ther. 2019;12:9927–9939.
   PubMed Web of Science ®Google Scholar
• Du SM. The SNHG16/miR-30a axis promotes breast cancer cell proliferation and invasion by regulating RRM2. Neoplasma. 2020;67(3):567–575.
   PubMed Web of Science ®Google Scholar
• Yuan FH, Chen YL, Zhao Y, et al. microRNA-30a inhibits the liver cell proliferation and promotes cell apoptosis through the JAK/STAT signaling pathway by targeting SOCS-1 in rats with sepsis. J Cell Physiol. 2019;234(10):17839–17853.
   PubMed Web of Science ®Google Scholar
• Mao H, Sheng J, Jia J, et al. Aberrant SLC6A14 expression promotes proliferation and metastasis of colorectal cancer via enhancing the JAK2/STAT3 pathway. Onco Targets Ther. 2021;14:379–392.
   PubMed Web of Science ®Google Scholar
• Zhou C, Wei W, Ma J, et al. Cancer-secreted exosomal miR-1468-5p promotes tumor immune escape via the immunosuppressive reprogramming of lymphatic vessels. Mol Ther. 2021;29(4):1512–1528.
   Google Scholar
• Liu L, Zhang Z, Zhang G, et al. Down-regulation of PADI2 prevents proliferation and epithelial-mesenchymal transition in ovarian cancer through inhibiting JAK2/STAT3 pathway in vitro and in vivo, alone or in combination with olaparib. J Transl Med. 2020;18(1):357.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann N Y Acad Sci. 2009;1171:59–76.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Kim HJ, Yang CS, et al. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. Mol Ther. 2014;22(7):1254–1265.
   PubMed Web of Science ®Google Scholar
• Zhuang S, Li L, Zang Y, et al. RRM2 elicits the metastatic potential of breast cancer cells by regulating cell invasion, migration and VEGF expression via the PI3K/AKT signaling. Oncol Lett. 2020;19(4):3349–3355.
   PubMed Web of Science ®Google Scholar
• Heinrich PC, Behrmann I, Haan S, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(Pt 1):1–20.
   PubMed Web of Science ®Google Scholar
• Li Y, Guo G, Song J, et al. B7-H3 promotes the migration and invasion of human bladder cancer cells via the PI3K/Akt/STAT3 signaling pathway. J Cancer. 2017;8(5):816–824.
   PubMed Web of Science ®Google Scholar
• Wang CX, Xiong HF, Wang S, et al. Overexpression of TEM8 promotes ovarian cancer progression via Rac1/Cdc42/JNK and MEK/ERK/STAT3 signaling pathways. Am J Transl Res. 2020;12(7):3557–3576.
   PubMed Web of Science ®Google Scholar
• Yan M, Gu S, Pan C, et al. MC-LR-induced interaction between M2 macrophage and biliary epithelial cell promotes biliary epithelial cell proliferation and migration through regulating STAT3. Cell Biol Toxicol. 2021. DOI:10.1007/s10565-020-09575-9
   Web of Science ®Google Scholar
• Wang J, Yi Y, Chen Y, et al. Potential mechanism of RRM2 for promoting cervical cancer based on weighted gene co-expression network analysis. Int J Med Sci. 2020;17(15):2362–2372.
   PubMed Web of Science ®Google Scholar
• Xiong M, Zhuang K, Luo Y, et al. KIF20A promotes cellular malignant behavior and enhances resistance to chemotherapy in colorectal cancer through regulation of the JAK/STAT3 signaling pathway. Aging (Albany NY). 2019;11(24):11905–11921.
   PubMedGoogle Scholar
• Cheon JH, Kim JY, Lee BM, et al. P-gp inhibition by XL019, a JAK2 inhibitor, increases apoptosis of vincristine-treated resistant KBV20C cells with increased p21 and pH2AX expression. Anticancer Res. 2017;37(12):6761–6769.
   PubMed Web of Science ®Google Scholar